Vetr cut shares of AbbVie (NYSE:ABBV) from a strong-buy rating to a buy rating in a report released on Monday morning. Vetr currently has $113.08 target price on the stock.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of AbbVie from a buy rating to a hold rating in a research note on Friday, January 5th. Jefferies Group lifted their target price on shares of AbbVie from $115.00 to $120.00 and gave the company a buy rating in a research note on Thursday, January 4th. Piper Jaffray Companies reaffirmed a buy rating on shares of AbbVie in a research note on Tuesday, January 2nd. BMO Capital Markets set a $84.00 target price on shares of AbbVie and gave the company a hold rating in a research note on Wednesday, December 20th. Finally, ValuEngine lowered shares of AbbVie from a strong-buy rating to a buy rating in a research note on Friday, December 1st. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. AbbVie currently has an average rating of Buy and a consensus price target of $100.94.

Shares of AbbVie (NYSE:ABBV) opened at $99.27 on Monday. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. The firm has a market cap of $158,250.00, a price-to-earnings ratio of 24.09, a PEG ratio of 1.20 and a beta of 1.53. AbbVie has a 52-week low of $59.27 and a 52-week high of $101.28.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.02. The company had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.21 EPS. sell-side analysts expect that AbbVie will post 5.55 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.86%. This is a boost from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date of this dividend is Thursday, January 11th. AbbVie’s payout ratio is presently 62.14%.

In related news, insider Henry O. Gosebruch sold 18,300 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the completion of the sale, the insider now directly owns 81,287 shares in the company, valued at $7,360,537.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Timothy J. Richmond sold 87,040 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the sale, the senior vice president now owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders have sold 494,676 shares of company stock valued at $47,237,938 over the last three months. 0.23% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ABBV. Jennison Associates LLC bought a new stake in AbbVie during the third quarter valued at approximately $544,418,000. Capital International Investors grew its position in AbbVie by 137.7% during the third quarter. Capital International Investors now owns 7,854,929 shares of the company’s stock valued at $697,989,000 after buying an additional 4,550,954 shares during the period. Vanguard Group Inc. grew its position in AbbVie by 3.3% during the second quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock valued at $8,405,409,000 after buying an additional 3,706,941 shares during the period. Janus Henderson Group PLC grew its position in AbbVie by 1,949.7% during the second quarter. Janus Henderson Group PLC now owns 3,833,535 shares of the company’s stock valued at $277,967,000 after buying an additional 3,646,510 shares during the period. Finally, Orbis Allan Gray Ltd grew its position in AbbVie by 35.7% during the second quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock valued at $921,233,000 after buying an additional 3,340,038 shares during the period. Institutional investors own 69.18% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/abbvie-abbv-lowered-to-buy-at-vetr/1803737.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.